Low circulating adiponectin levels are associated with an increased risk of several obesity-related malignancies, including breast, endometrial, colon, gastric, and prostate cancers.
Systematic Review
Recent studies have demonstrated that obesity is a significant risk factor for the development of several malignancies, but the mechanisms underlying this relationship remain to be fully elucidated. Adiponectin, an adipocyte secreted endogenous insulin sensitizer, appears to play an important role not only in glucose and lipid metabolism but also in the development and progression of several obesity-related malignancies. In this review, we present recent findings on the association of adiponectin with several malignancies as well as recent data on underlying molecular mechanisms that provide novel insights into the association between obesity and cancer risk. We also identify important research questions that remain unanswered.
Kelesidis et al. (Tue,) conducted a systematic review in Cancer (obesity-related malignancies). Adiponectin was evaluated. Low circulating adiponectin levels are associated with an increased risk of several obesity-related malignancies, including breast, endometrial, colon, gastric, and prostate cancers.